Premium
Soy Protein Supplementation May Play a Role in Decreasing the Risk of Bone Fracture through Affecting Hematopoietic Factors in Young and Old Men
Author(s) -
Akhavan Neda S,
Pourafshar Shirin,
Navaei Negin,
Arjmandi Bahram H.
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.lb344
Subject(s) - osteoporosis , bone mineral , medicine , bone density , hematocrit , haematopoiesis , endocrinology , fragility fracture , bone fracture , biology , stem cell , radiology , genetics
Osteoporosis is a health problem which is associated with bone fracture and bone fragility. Bone loss is an accompaniment of aging which occurs at about age of 50 in men. Several studies have suggested that populations with high dietary soy intake have a lower prevalence of osteoporosis and bone fracture. Soy protein (SP) is a rich source of phytoestrogen which has been shown to diminish the loss of bone mineral density as well as decrease the risk of fracture. In this study, we have focused on 3‐month SP supplementation in young and old men in order to investigate the effect of SP on hematopoietic factors. Healthy men (59.2±17.6y) were assigned to consume 40g of either SP or milk‐based protein (MP) daily for 3 months in a double blind, randomized, controlled, paralleled design. ANOVA and paired t‐test were used to determine whether there were statistical significances in hematopoietic variables of interest. Red blood cells and hematocrit either increased ( P =0.04) or tended to increase (P=0.09) in those who consumed SP, respectively. On the other hand basophil (BAS) value tended to increase ( P =0.07) in those who were on MP diet. This suggests that MP may not be able to prevent the rise in BAS associated with aging. Increased apoptosis of BAS observed as a result of aging may be due to persistent inflammation. The findings of this study suggest that SP consumption may inhibit the age‐associate rise in certain hematopoietic parameters.